Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.44 |
| ▸ | PPARD | Q03181 | 11/20 | 0.44 |
| ▸ | PPARA | Q07869 | 12/20 | 0.43 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3775489 | 0.87 | PPARD (0.42) | PPARGPPARDPPARAIKBKBHDAC3 | |
| SCHEMBL4476959 | 0.81 | PPARG (0.45) | PPARGPPARDPPARAIKBKBHDAC3 | |
| SCHEMBL3775173 | 0.80 | PPARG (0.47) | PPARGPPARDPPARAIKBKBHDAC3 | |
| SCHEMBL3764083 | 0.76 | KDM4E (0.48) | PPARGPPARDPPARAIKBKBPTPN1 | |
| SCHEMBL9831925 | 0.75 | PTPN1 (0.51) | PPARGPPARDPPARAIKBKBPTPN1 | |
| SCHEMBL4467452 | 0.75 | PPARD (0.58) | PPARGPPARDPPARAIKBKBHDAC3 | |
| SCHEMBL4486372 | 0.72 | PPARD (0.44) | PPARGPPARDPPARAIKBKBHDAC3 | |
| SCHEMBL18003565 | 0.72 | IKBKB (0.43) | PPARGPPARDPPARAIKBKBPTPN1 | |
| SCHEMBL4478993 | 0.71 | PPARG (0.44) | PPARGPPARDPPARAIKBKBPTPN1 | |
| SCHEMBL4890697 | 0.70 | PPARA (0.54) | PPARGPPARAIKBKBPTPN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1934206-B1 | PHENYL- AND PYRIDYL-I, 2 , 4 -OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2011-12-14 | — | — | EP | disclosed |
| EP-1934206-B1 | PHENYL- AND PYRIDYL-I, 2 , 4 -OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2011-12-14 | — | — | EP | disclosed |
| US-7851493-B2 | Phenyl-1,2,4-oxadiazolone derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2010-12-14 | — | — | US | disclosed |
| US-7851493-B2 | Phenyl-1,2,4-oxadiazolone derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2010-12-14 | — | — | US | disclosed |
| US-7851493-B2 | Phenyl-1,2,4-oxadiazolone derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2010-12-14 | — | — | US | disclosed |
| US-20090281084-A1 | PHENYL-1,2,4-OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-11-12 | — | — | US | disclosed |
| US-20090281084-A1 | PHENYL-1,2,4-OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-11-12 | — | — | US | disclosed |
| US-20090281084-A1 | PHENYL-1,2,4-OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-11-12 | — | — | US | disclosed |
| US-20080287409-A1 | PHENYL AND PYRIDINYL-1,2,4-OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | SANOFI-AVENTIS (FR) | 2008-11-20 | — | — | US | disclosed |
| US-20080287409-A1 | PHENYL AND PYRIDINYL-1,2,4-OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | SANOFI-AVENTIS (FR) | 2008-11-20 | — | — | US | disclosed |
| US-20080287409-A1 | PHENYL AND PYRIDINYL-1,2,4-OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | SANOFI-AVENTIS (FR) | 2008-11-20 | — | — | US | disclosed |
| EP-1934206-A1 | PHENYL- AND PYRIDYL-I, 2 , 4 -OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007039172-A1 | PHENYL- AND PYRIDYL-I, 2 , 4 -OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039172-A1 | PHENYL- AND PYRIDYL-I, 2 , 4 -OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287409-A1 | PHENYL AND PYRIDINYL-1,2,4-OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | PPARD, PPARA, PPARG | PPARG 3/4885PPARD 1/4885PPARA 2/4885 |
| US-20090281084-A1 | PHENYL-1,2,4-OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | PPARD, PPARA, PPARG | PPARG 3/4885PPARD 1/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.